HWN Suggests

A New Pain Killer on the Market: The Good and the Not So Good on Journavx

There is a lot of discussion about the newest medicine on the market... While Journavx has shown promise in managing acute pain, its efficacy in chronic pain conditions remains under investigation. A Phase 2 study focusing on lumbosacral radiculopathy (lower back pain) did not demonstrate a significant benefit over placebo, highlighting the challenges in treating chronic pain and the need for further research. In summary, Journavx is not very impressive. It has a weak pain killing strength and is effective only in acute surgical pain and not for chronic pain. As with any medication, it is essential to weigh its benefits against potential risks and to consider individual patient needs when determining…

read full article

Featured

  Journavx: A Promising Opioid Alternative, but Not a Silver Bullet

Nevertheless, Journavx appears to be a real breakthrough drug, opening the door for a new class of pain relievers for patients to access. This is good news. A caveat: Pain is subjective, and analgesics affect individuals differently. The clinical trials found it roughly equivalent to a standard dose of hydrocodone. Hydrocodone is not as potent as oxycodone and doesn’t work for everyone, though it works for many people.

 A new, non-opioid pain drug is here. Getting it to patients could be agony

After decades of research, Vertex Pharmaceuticals has an approved pain medicine. Can one of the most powerful biotechs contend with a healthcare system that’s long favored opioids? Unlike all other approved pain drugs, Vertex’s blocks tube-shaped proteins found almost exclusively in nerve cells located outside the brain and spinal cord. These “NaV1.8” proteins act like cell towers, transmitting pain waves to the central nervous system. In addition to being effective, studies have found Journavx to be remarkably safe. It doesn’t appear to have the addictive qualities of opioids, which bribe the brain’s pleasure centers, and compared to a placebo it actually was associated with lower rates of common ailments like nausea, constipation and headache.

Articles of Interest

Journavx: A Newly-Approved, Non-Opioid Pain Medication

This novel opioid-free pain medication offers a safer alternative for managing pain, researchers have noted barriers to widespread utilization of this medication. Journavx is currently only approved for use in treating acute pain. The results of the clinical trials conducted so far focused on its effectiveness in treating short-term or acute pain, often as seen following a surgery or accident5. However, Vertex has reported positive results of its use in treating chronic pain in patients with diabetic peripheral neuropathy2. The manufacturer has also announced that a phase 3 clinical trial is in progress, hopefully making the drug a suitable option in the future for individuals experiencing chronic and/or moderate pain.

Suzetrigine (Journavx) — A Sodium Channel Blocker for Acute Pain

In two 48-hour double-blind trials in adults with moderate to severe acute postoperative pain, the oral selective sodium channel blocker suzetrigine (Journavx) was more efficacious than placebo, but not hydrocodone/acetaminophen. Suzetrigine appears to be well tolerated and to not cause addiction or dependence, but it is expensive. For most patients with moderate to severe acute pain, an NSAID should be tried first. Suzetrigine could be a reasonable alternative when NSAIDs or opioids are ineffective or the risk of adverse effects with their use is unacceptable. The efficacy and safety of suzetrigine for treatment of subacute or chronic pain is unknown.

'I think it's a game-changer for acute pain management'

Sylvia Wilson, M.D., specializes in regional anesthesia and acute pain after surgery. “It's a big deal. It's a whole new class of drugs. I'm excited to see where it goes and what happens,” she said of the new medication. Meron Selassie, M.D., helps people suffering from chronic pain. Journavx has not been approved for them yet – only for people with short-term pain. Studies are underway that could change that one day. In the meantime, Selassie said: “I think it's a game-changer for acute pain management in high-risk populations, post-surgical pain management – if it can be affordable for people.”

Can this new drug promise pain relief without peril?

The drug’s approval does not extend to chronic pain treatment. Still, Dr. Cohen sees the breakthrough as a positive step for the future of pain management. “The approval will hopefully open the door for more non-opioid treatments for both acute and chronic pain, including those that target other sodium channels.”

Journavx and the Opioid Crisis: A Pharmacist’s Public Health Perspective

While this makes Journavx an exciting addition to the pain management landscape, it is important to manage expectations about its impact on the opioid crisis. Currently, Journavx is only approved for acute pain, meaning it is not a substitute for opioids in managing chronic pain conditions, which are a major driver of long-term opioid use and addiction (Smith, 2025). From a public health and clinical perspective, Journavx has the potential to redefine post-surgical and acute pain treatment by serving as a first-line alternative to opioids for procedures where moderate pain relief is required.

Journavx: Long awaited non-opioid treatment for acute pain hits the market

This new oral painkiller — the first approved by the FDA in more than 20 years — could offer an alternative to highly addictive opioids. The new drug targets a very specific sodium channel – Nav1.8 – that is only located in nerve cells that send signals – including pain – to the brain, Rzasa Lynn said. Local anesthetics that numb tissue are also sodium channel blockers, Rzasa Lynn said. However, they are “non-specific,” meaning they block not one, but all channels.

New Painkiller Could Bring Relief to Millions—Without Addiction Risk

The medication initially known as VX-548 blocks sodium channels in nerves, blocking pain signals before they reach the brain.

Painkillers without the addiction? The new wave of non-opioid pain relief

Pharma firms are developing drugs that avoid the brain’s opioid receptors to minimise the risks of dependence and overdoses, but not all experts are convinced. Journavx selectively blocks a VGSC called Nav1.8 that is predominantly found in pain-sensing neurons in the peripheral nervous system, says David Altshuler, chief scientific officer of Vertex. The drug does not act on the brain the way opioids do and instead acts outside the brain, meaning there is no addiction risk.

What Is Journavx, the New Opioid-Free Painkiller from Vertex?

Clinical trials showed that the medication dampened pain as effectively as an opioid-based painkiller. And perhaps most importantly, suzetrigine does so without the same risk of addiction.

Why a new opioid alternative is out of reach for some pain patients

But the new pills are expensive, and not everyone has been able to access them, thanks to a narrowly-focused FDA approval and limited insurance coverage Abrams' doctor wanted him to be able to try Journavx. But the FDA only approved the medication for short-term use for acute pain, which is usually defined as lasting less than three months, such as right after surgery. Because Abrahm's pain is chronic, his insurance wouldn't cover it.

Will the new non-addictive painkiller approved by the FDA take the place of opioid drugs? Who should get a prescription?

“I would say this is not going to take out opioids from the market completely,” he says. For starters, Journavx has yet to show evidence of reducing chronic pain or the severe pain associated with late stage cancers. But “it’s a big step,” Thakur says. “People have been talking about sodium channel innovators for a long time. It’s a billion dollar loss when you try to develop drugs, take it to advanced stages and they fail. I’m very happy to see that Vertex did an amazing job in advancing this compound.”

Resources

Journavx

JOURNAVX is a nonopioid medication used to treat adults with moderate-to-severe acute pain. JOURNAVX works by reducing pain signals before they reach the brain.